Trending...
- Expert E-Bike Safety Advocate Issues Urgent Warning Following Recent Southern California Fatalities
- RAS AP Consulting Advances to RFP Stage in Heidelberg Materials' SAP Vendor & Customer Master Data Modernization Initiative
- David Cavanagh Launches AI SEO Company For ChatGPT And AI Search Visibility
WEST CHESTER, Pa., Sept. 16, 2021 /PRNewswire/ -- VESTECK, Inc., an early-stage medical device company, is pleased to announce the additional close of funds totaling >$5.2M of Series A financing, which includes conversion of all existing convertible notes.
Philadelphia area investors BioAdvance (https://www.bioadvance.com/) and Angel Network (https://angelstarventures.com/) Kennett Square, PA lead these additional investments, joined by several other investors.
The Series A funds will support the manufacturing of products, pre-clinical testing and completion of in human procedures, prior to our clinical study for FDA clearance.
VESTECK has designed a platform technology comprised of 6 devices that integrate the delivery of nitinol sutures into a catheter, improving clinical outcomes for endovascular aortic aneurysm patients.
Dr. Rick Jones, BioAdvance Partner said, "BioAdvance is very excited to support the VESTECK "Suture-Tight" technology and team. We appreciate that VESTECK is answering a significant global unmet need for patients and physicians."
More on The PennZone
The "Suture-Tight" catheter delivers nitinol sutures more easily than current endovascular or surgical options, securing endovascular aortic repair grafts to the aorta at initial implant or in repair procedures.
Dr. David H. Deaton, Chief Medical Officer, says, "the Suture-Tight catheter makes the process faster, easier and safer for physicians and patients. Suture-Tight will become the standard of care in EVAR."
Vesteck expects to bring significant incremental revenue to an aortic repair market projected to be $4.5B by 2028.
VESTECK CEO Joe Rafferty stated, "We are absolutely honored that our $3.5M Series A round has been over subscribed to this extent, a further recognition of this significant opportunity."
About Vesteck Inc.:
VESTECK, Inc. (WWW.VESTECK.com) is an early-stage medical device company focused on bringing their proprietary technology to the aortic repair, structural heart and GI markets.
Their first product, the "Suture-Tight" nitinol suture delivery catheter will bring a novel technology to endovascular aortic repair market solving a significant global challenge for physicians and patients.
VESTECK was represented by Kevin M. Granahan of Fox Rothschild LLP
MEDIA CONTACTS:
BioAdvance VESTECK, Inc.
Dr. Frederick Jones Joe Rafferty
Partner CEO
(508) 314-5347 610-457-7324
SOURCE VESTECK, Inc.
Related Links
http://VESTECK.com
Philadelphia area investors BioAdvance (https://www.bioadvance.com/) and Angel Network (https://angelstarventures.com/) Kennett Square, PA lead these additional investments, joined by several other investors.
The Series A funds will support the manufacturing of products, pre-clinical testing and completion of in human procedures, prior to our clinical study for FDA clearance.
VESTECK has designed a platform technology comprised of 6 devices that integrate the delivery of nitinol sutures into a catheter, improving clinical outcomes for endovascular aortic aneurysm patients.
Dr. Rick Jones, BioAdvance Partner said, "BioAdvance is very excited to support the VESTECK "Suture-Tight" technology and team. We appreciate that VESTECK is answering a significant global unmet need for patients and physicians."
More on The PennZone
- Inside-Out Hollywood: The Relentless Rise of Joseph Nybyk (AKA Joseph Neibich)
- SRK Collective Media Group Launches with a Modern Approach to Media, Authority Building, and Cultural Visibility
- MSBG Corporation Acquires GridWatch US Telemetry Automation System
- TAYP Expands Athlete Exposure Platform Beyond Georgia With New Push Into Virginia and the 757
- KT Medical Staffing Expands Concierge Nursing and Private Duty Nursing Services in Orange County
The "Suture-Tight" catheter delivers nitinol sutures more easily than current endovascular or surgical options, securing endovascular aortic repair grafts to the aorta at initial implant or in repair procedures.
Dr. David H. Deaton, Chief Medical Officer, says, "the Suture-Tight catheter makes the process faster, easier and safer for physicians and patients. Suture-Tight will become the standard of care in EVAR."
Vesteck expects to bring significant incremental revenue to an aortic repair market projected to be $4.5B by 2028.
VESTECK CEO Joe Rafferty stated, "We are absolutely honored that our $3.5M Series A round has been over subscribed to this extent, a further recognition of this significant opportunity."
About Vesteck Inc.:
VESTECK, Inc. (WWW.VESTECK.com) is an early-stage medical device company focused on bringing their proprietary technology to the aortic repair, structural heart and GI markets.
Their first product, the "Suture-Tight" nitinol suture delivery catheter will bring a novel technology to endovascular aortic repair market solving a significant global challenge for physicians and patients.
VESTECK was represented by Kevin M. Granahan of Fox Rothschild LLP
MEDIA CONTACTS:
BioAdvance VESTECK, Inc.
Dr. Frederick Jones Joe Rafferty
Partner CEO
(508) 314-5347 610-457-7324
SOURCE VESTECK, Inc.
Related Links
http://VESTECK.com
Filed Under: Business
0 Comments
Latest on The PennZone
- San Francisco Writer Wins Webby Award, Internet's Highest Honor, for Website Based on her Novel
- EDC Weekend Comedy Special Featuring Don Barnhart & Friends — Use Promo Code FRIEND for 50% Off
- N Y S E: OTH Off The Hook YS Is Building a Vertically Integrated Marine Empire — And Investors Are Starting to Notice
- Concierge Title Agency Merges with Independence Title, Inc. to Deliver an Expanded Concierge Closing Experience Across South Florida
- Together We Dance Foundation Steps Up for Family in Need of Safe Transportation
- Grow My Security Company Launches Next-Generation Website and Expands Strategic Marketing Solutions for the Security Industry
- $4.8M in Contracted AI Revenue with Projections of $30M Over 6-12 Months for Diversified AI Software and Platform-Based Services Provider XMax Inc
- Michelangelo's Great Secret Hiding in Plain Sight
- Virginia Marchese's Paradox: A Nation Still Deciding Who Belongs Examines Race, Migration, Law, and America's Unfinished Struggle for Equality
- From Blank Page to Published Book
- Larry R. Wasion's Jump Gate III RoadMaker Blends Cutting-Edge Sci-Fi with High-Stakes Space Exploration and Complex Technologies
- Ed, Edd n Eddy, Resident Evil, Anime Voice Actors Augment FAN EXPO Philadelphia Lineup
- American Mensa and Davidson Institute Join Forces To Strengthen Support for Profoundly Gifted Youth
- SpeedyIndex Rolls Out Automated API for Mass URL Verification, Solving the Backlink Blind Spot for SEO Agencies
- KLEKT Announces Appointment of Jay Kimpton to Board of Directors
- Michigan Attorney General Closed FGM Licensing Investigations Months Before Federal Case Ended, Records Show
- Client 1st Financial and Keystone Financial Management Donate 550+ Pounds of Food to New Bethany Inc
- Mensa Foundation Event Reframes Brain Health for Every Age
- DLT Resolution, Inc. (Stock Symbol: DLTI) Expands Into the $224 Billion Life Settlements Market While Accelerating Telecom Growth Across Canada
- Pollock Begg Partner Joseph R. Williams Featured on 'CEOs You Should Know' Podcast